Scientists have found new target of treating blood cancer

A proteoglycan molecule called CD99 is frequently found in stem cells from patients with blood cancer, including acute myeloid leukemia (AML) and associated myelodysplastic syndrome (MDS). The detailed report was published in the January 25 issue of the journal Science Translational Medicine. Based on this finding, the researchers designed an antibody that recognizes and disrupts CD99-coated leukemic cells, which have now been demonstrated in human and mouse cells. Antibodies are immune proteins that attach to specific targets, just like proteins that invade viral surfaces. In recent years, researchers have been able to control antibodies so they can target pathogenic molecules by conducting research involving recombinant horse proteins.

"Our findings not only confirm new stem cell molecules that drive human malignancies, but also show that these antibodies can kill human AML stem cells directly," the researchers said.

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are caused by abnormal stem cells in the bone marrow, and patients show anemia, an increased risk of infection and bleeding. The findings are based on an understanding of cancer. Just as normal tissue, including stem cells causing other cells, this "cancer stem cell", is a major factor in many types of cancer. In AML, a small percentage of leukemic stem cells can't grow into mature red or white blood cells. Most of the initial treatment of leukemia is significant, but it often relapses.

The researchers were interested in CD99 in the observation of AML and MDS cells. Previously, CD99 was crucial for the rare bone tumor of Ewing's sarcoma, so the researchers wanted to find out the effect of CD99 on blood cancer. After comparing 79 AML patients and 24 MDS patients, the researchers found that about 85% of the patients showed high levels of CD99. High levels of CD99 were able to separate diseased stem cells from normal stem cells. The researchers then designed the antibody and bound it to CD99. It was found that when the antibody binds to CD99 on the surface of cancer cells, it sends a signal to the inside of the cell to increase the activity of SRC-family kinase.

"With the appropriate support, we believe we can quickly identify the best antibodies for patients and begin clinical trials," the researchers concluded. By the way, Flarebio provides you with superior recombinant proteins like recombinant CDH2 at good prices.